BMS, Simcere in deal for CETP inhibitor

Bristol-Myers Squibb Co. (NYSE:BMY) granted Simcere Pharmaceutical Group (NYSE:SCR) exclusive rights in China to develop and commercialize preclinical cardiovascular compound BMS-795311. Bristol-Myers retains rights elsewhere. BMS-795311 is a small molecule cholesteryl ester transfer protein (CETP) inhibitor. Financial details were not disclosed. Simcere was up $0.25 to $7.60 on Wednesday. ...